Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(04): 565
DOI: 10.4103/ijmpo.ijmpo_268_19
Images in Oncology

Young Man with Hodgkin Disease with Skin Rash

Suresh VS Attili
Department of Medical Oncology, Omega Hospital, Hyderabad, Telangana, India
,
Janarthan Babu
Department of Medical Oncology, AIG Hospital, Hyderabad, Telangana, India
,
V Nishit
Department of Medical Oncology, Omega Hospital, Hyderabad, Telangana, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
   Permissions and Reprints

A 34-year-old male diagnosed with Hodgkin’s lymphoma on ABVD chemotherapy (it includes the drugs doxorubicin hydrochloride [adriamycin], bleomycin sulfate, vinblastine sulfate, and dacarbazine) presented with pruritic skin lesions – which changed color from reddish to dark hyperpigmented ones over 10 days – not responding to topical steroids or antihistamines [Figure 1]. The second course presented with worse reactions, which got better after cold packing over the rashes before chemotherapy.

Zoom Image
Figure 1: Skin lesions look like below – which are predominantly over the trunk – sparing the limbs and face having whip lash appearance


Publication History

Received: 24 December 2019

Accepted: 06 January 2020

Article published online:
03 June 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • Reference

  • 1 Changal KH, Raina H, Changal QH, Raina M. Bleomycin-induced flagellate erythema: A rare and unique drug rash. West Indian Med J 2014; 63: 807-9
    PubMedGoogle Scholar